Polarean Imaging PLC Appointment of Nominated Adviser and Broker (9323N)
January 24 2019 - 1:00AM
UK Regulatory
TIDMPOLX
RNS Number : 9323N
Polarean Imaging PLC
24 January 2019
24 January 2019
Polarean Imaging Plc
("Polarean" or the "Company")
Appointment of Nominated Adviser and Broker
Polarean Imaging plc (AIM: POLX), the medical--imaging
technology company, with a proprietary drug--device combination
product for the magnetic resonance imaging (MRI) market, announces
that pursuant to the proposed merger between SP Angel Corporate
Finance LLP ("SP Angel") and Northland Capital Partners Ltd, it has
appointed SP Angel as its Nominated Adviser and Broker with
immediate effect.
AIM Rule 17 Notice
Richard Hullihen, the Company's Chief Executive Officer, was
previously a Director of M2M Imaging Australia Pty Ltd ("M2M
Australia"). M2M Australia was placed in voluntary administration
in 2013 while Richard Hullihen was on the board. M2M Australia was
subsequently liquidated and dissolved in 2015.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell
Lindsay Mair
MC Services (European IR) Tel: +49 (0)89 210 2280
Raimund Gabriel
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001
Helen Cresswell Mob: +44 (0)7841 917 679
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution functional
magnetic resonance imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate than current methods. The annual
burden of pulmonary disease in the US is estimated to be over US
$150 billion.
The Group is currently undertaking Phase III Non-Inferiority
Clinical Trials for (129) Xe at Duke University and University of
Virginia.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPSELFWDFUSEFF
(END) Dow Jones Newswires
January 24, 2019 02:00 ET (07:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2024 to May 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From May 2023 to May 2024